-
1
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: an update
-
COI: 1:CAS:528:DC%2BD1MXkslWjs7o%3D, PID: 19330875
-
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.
-
(2009)
Hepatology.
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
-
2
-
-
33646852746
-
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
-
PID: 16702586
-
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
-
(2006)
Ann Intern Med.
, vol.144
, pp. 705-714
-
-
Armstrong, G.L.1
Wasley, A.2
Simard, E.P.3
-
3
-
-
84875054629
-
A nationwide seroepidemiology of hepatitis C virus infection in South Korea
-
PID: 23356674
-
Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int. 2013;33:586–594.
-
(2013)
Liver Int
, vol.33
, pp. 586-594
-
-
do Kim, Y.1
Kim, I.H.2
Jeong, S.H.3
-
4
-
-
0036829816
-
Natural history of chronic hepatitis C
-
PID: 12407575
-
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46.
-
(2002)
Hepatology.
, vol.36
, pp. S35-S46
-
-
Seeff, L.B.1
-
5
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
-
COI: 1:CAS:528:DC%2BD3MXntF2qtb8%3D, PID: 11583749
-
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.
-
(2001)
Lancet.
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
6
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
COI: 1:CAS:528:DC%2BD38Xnt12rtb0%3D, PID: 12324553
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
-
(2002)
N Engl J Med.
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
7
-
-
1542378867
-
Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
-
COI: 1:CAS:528:DC%2BD2cXitlOktrg%3D, PID: 14996676
-
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
-
(2004)
Ann Intern Med.
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, H.2
Morgan, T.R.3
-
8
-
-
78049476361
-
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
-
COI: 1:CAS:528:DC%2BC3cXhtlKhurrJ, PID: 20637202
-
Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.
-
(2010)
Gastroenterology.
, vol.139
, pp. 1593-1601
-
-
Swain, M.G.1
Lai, M.Y.2
Shiffman, M.L.3
-
9
-
-
62749203302
-
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients
-
COI: 1:CAS:528:DC%2BD1MXjvFOnurY%3D, PID: 19072828
-
George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.
-
(2009)
Hepatology.
, vol.49
, pp. 729-738
-
-
George, S.L.1
Bacon, B.R.2
Brunt, E.M.3
-
10
-
-
0012431804
-
Report of the expert committee on the diagnosis and classification of diabetes mellitus
-
Anonymous. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5–S20.
-
(2003)
Diabetes Care.
, vol.26
, pp. S5-S20
-
-
Anonymous1
-
11
-
-
84864412353
-
Revision and update on clinical practice guideline for liver cirrhosis
-
PID: 22511898
-
Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1–21.
-
(2012)
Korean J Hepatol.
, vol.18
, pp. 1-21
-
-
Suk, K.T.1
Baik, S.K.2
Yoon, J.H.3
-
12
-
-
0029778988
-
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group
-
COI: 1:STN:280:DyaK28zhvFClug%3D%3D, PID: 8690394
-
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.
-
(1996)
Hepatology.
, vol.24
, pp. 289-293
-
-
Bedossa, P.1
Poynard, T.2
-
13
-
-
0036733622
-
-
Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023–1032; quiz 1033-1024
-
Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023–1032; quiz 1033-1024.
-
-
-
-
14
-
-
79952213055
-
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)
-
COI: 1:CAS:528:DC%2BC3MXkt1Clt78%3D, PID: 21319193
-
Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–894.
-
(2011)
Hepatology.
, vol.53
, pp. 885-894
-
-
Jung, K.S.1
Kim, S.U.2
Ahn, S.H.3
-
15
-
-
58149119720
-
Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
-
PID: 18367856
-
Kim KT, Han SY, Kim JH, et al. Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. Korean J Hepatol. 2008;14:36–45.
-
(2008)
Korean J Hepatol
, vol.14
, pp. 36-45
-
-
Kim, K.T.1
Han, S.Y.2
Kim, J.H.3
-
16
-
-
84862910095
-
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study
-
COI: 1:CAS:528:DC%2BC38Xmt1ylsbk%3D, PID: 22375178
-
Park SH, Park CK, Lee JW, et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver. 2012;6:98–106.
-
(2012)
Gut Liver.
, vol.6
, pp. 98-106
-
-
Park, S.H.1
Park, C.K.2
Lee, J.W.3
-
17
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
COI: 1:CAS:528:DC%2BD1MXhtFaju7%2FM, PID: 19749758
-
Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104.
-
(2009)
Nat Genet.
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
-
18
-
-
70349966196
-
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
-
COI: 1:CAS:528:DC%2BD1MXhtFentb%2FJ, PID: 19759533
-
Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
-
(2009)
Nature.
, vol.461
, pp. 798-801
-
-
Thomas, D.L.1
Thio, C.L.2
Martin, M.P.3
-
19
-
-
82755197774
-
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin
-
COI: 1:CAS:528:DC%2BC3MXhsVOltLvN, PID: 21907615
-
Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol. 2011;52:363–366.
-
(2011)
J Clin Virol.
, vol.52
, pp. 363-366
-
-
Lyoo, K.1
Song, M.J.2
Hur, W.3
-
20
-
-
84879495637
-
Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
-
PID: 23323251
-
Jeong SH, Jung YK, Yang JW, et al. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Clin Mol Hepatol. 2012;18:360–367.
-
(2012)
Clin Mol Hepatol.
, vol.18
, pp. 360-367
-
-
Jeong, S.H.1
Jung, Y.K.2
Yang, J.W.3
-
21
-
-
80052360000
-
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients
-
COI: 1:CAS:528:DC%2BC3MXhtlWqsrvK, PID: 21501223
-
Sinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011;26:1374–1379.
-
(2011)
J Gastroenterol Hepatol.
, vol.26
, pp. 1374-1379
-
-
Sinn, D.H.1
Kim, Y.J.2
Lee, S.T.3
-
22
-
-
0036830454
-
Side effects of therapy of hepatitis C and their management
-
PID: 12407599
-
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237–S244.
-
(2002)
Hepatology.
, vol.36
, pp. S237-S244
-
-
Fried, M.W.1
-
23
-
-
70449711352
-
Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C
-
COI: 1:CAS:528:DC%2BD1MXhtlyqtrzN, PID: 19721856
-
Kwon JH, Bae SH, Choi JY, et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med. 2009;24:203–211.
-
(2009)
Korean J Intern Med.
, vol.24
, pp. 203-211
-
-
Kwon, J.H.1
Bae, S.H.2
Choi, J.Y.3
-
24
-
-
33745404151
-
Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea
-
PID: 16565604
-
Lee H, Choi MS, Paik SW, et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol. 2006;12:31–40.
-
(2006)
Korean J Hepatol
, vol.12
, pp. 31-40
-
-
Lee, H.1
Choi, M.S.2
Paik, S.W.3
-
25
-
-
84884988177
-
Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
-
PID: 23564522
-
Asahina Y, Tsuchiya K, Nishimura T, et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–1262.
-
(2013)
Hepatology.
, vol.58
, pp. 1253-1262
-
-
Asahina, Y.1
Tsuchiya, K.2
Nishimura, T.3
-
26
-
-
84926254753
-
Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes
-
Yamashita N, Ohho A, Yamasaki A, et al. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2013.
-
(2013)
J Gastroenterol
-
-
Yamashita, N.1
Ohho, A.2
Yamasaki, A.3
-
27
-
-
84856151318
-
Long-term cohort study of chronic hepatitis C according to interferon efficacy
-
COI: 1:CAS:528:DC%2BC38XjtlKnsLg%3D, PID: 21793911
-
Maruoka D, Imazeki F, Arai M, et al. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27:291–299.
-
(2012)
J Gastroenterol Hepatol.
, vol.27
, pp. 291-299
-
-
Maruoka, D.1
Imazeki, F.2
Arai, M.3
-
28
-
-
33845927812
-
Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea
-
PID: 17191307
-
Kim JH, Han KH, Lee KS, et al. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J. 2006;47:793–798.
-
(2006)
Yonsei Med J.
, vol.47
, pp. 793-798
-
-
Kim, J.H.1
Han, K.H.2
Lee, K.S.3
-
29
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
COI: 1:CAS:528:DC%2BC3MXotVCku7Y%3D, PID: 21696307
-
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
-
(2011)
N Engl J Med.
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
30
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
COI: 1:CAS:528:DC%2BC3MXotVCrsrg%3D, PID: 21696308
-
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
-
(2011)
N Engl J Med.
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
31
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
COI: 1:CAS:528:DC%2BC3MXhtF2mtrrI, PID: 21916639
-
Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.
-
(2011)
N Engl J Med.
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
-
32
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
COI: 1:CAS:528:DC%2BC3MXkt1Chtrc%3D, PID: 21449783
-
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
-
33
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
COI: 1:CAS:528:DC%2BC3MXkt1Cht7k%3D, PID: 21449784
-
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
-
34
-
-
77951652616
-
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
-
COI: 1:CAS:528:DC%2BC3cXlsFKlu7c%3D, PID: 20346533
-
Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–657.
-
(2010)
J Hepatol.
, vol.52
, pp. 652-657
-
-
Cardoso, A.C.1
Moucari, R.2
Figueiredo-Mendes, C.3
-
35
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
PID: 18025443
-
Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.
-
(2007)
Ann Intern Med.
, vol.147
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
-
36
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
-
COI: 1:CAS:528:DC%2BD2sXjs1Gktbc%3D, PID: 17326216
-
Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.
-
(2007)
Hepatology.
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
-
37
-
-
77956635697
-
Outcome of sustained virological responders with histologically advanced chronic hepatitis C
-
COI: 1:CAS:528:DC%2BC3cXhtFyitr7P, PID: 20564351
-
Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844.
-
(2010)
Hepatology.
, vol.52
, pp. 833-844
-
-
Morgan, T.R.1
Ghany, M.G.2
Kim, H.Y.3
-
38
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
PID: 23268517
-
van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
-
(2012)
JAMA.
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
-
39
-
-
77049098144
-
Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis
-
PID: 20087166
-
Madhoun MF, Fazili J, Bright BC, et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci. 2010;339:169–173.
-
(2010)
Am J Med Sci.
, vol.339
, pp. 169-173
-
-
Madhoun, M.F.1
Fazili, J.2
Bright, B.C.3
-
40
-
-
77957774891
-
Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
-
Kawamura Y, Arase Y, Ikeda K, et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med. 2010;123:951–956 e951.
-
Am J Med. 2010;123
, vol.951-956
, pp. e951
-
-
Kawamura, Y.1
Arase, Y.2
Ikeda, K.3
|